BioSpace

FDA's latest rare disease framework seeks to prioritize consistency in flexibility

Following several recent initiatives, the FDA's newest rare disease framework sets out to standardize the agency's approach to scientific evidence and bring rare disease therapies to patients faster.

By BioSpace

1 min read
FDA's latest rare disease framework seeks to prioritize consistency in flexibility
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights